Literature DB >> 8180387

Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase.

M H Hsiao1, A L Yu, J Yeargin, D Ku, M Haas.   

Abstract

We have previously reported that greater than 60% of human leukemic T-cell lines possess mutations in the p53 tumor suppressor gene. To determine whether T-cell acute lymphoblastic leukemia (T-ALL) patient samples possess p53 mutations, we screened peripheral blood-and bone marrow-derived leukemia samples, taken at diagnosis and at relapse, for p53 mutations. Exons 4 through 9 and selected intron regions of the p53 gene were analyzed using polymerase chain reaction-single-strand conformation polymorphism and direct sequencing. p53 mutations were found in 0 of 15 T-ALL diagnosis samples, as compared with 10 of 36 (28%) T-ALL relapse samples. To determine whether p53 mutations play a role in the recurrence (relapse) of T-ALL, two special groups of T-ALL patients were studied: (1) a group of 8 relapse patients whose disease was refractory to chemotherapeutic treatment, and (2) a group of 6 "paired" T-ALL cell samples from patients for whom we possess both diagnosis and relapse samples. Three of 8 relapsed patients (37.5%) whose disease was refractory to the reinduction of remission by chemotherapy possessed missense mutations of the p53 gene. All 3 cases had mutations in exon 5. Among the paired samples, 3 of 6 patients harbored p53 mutations at disease recurrence, but possessed only wild-type p53 alleles at diagnosis. One case had mutation on exon 4, 1 case in exon 5, and 1 case in exon 8 with loss of heterozygosity. These data clearly indicate that recurrence of T-ALL is associated with missense mutations in p53. Our results indicate that (1) mutations of p53 do occur in T-ALL in vivo, and such mutations are associated with the relapse phase of the disease; and (2) p53 mutation is involved in the progression of T-ALL. This conclusion is supported by our observation that the introduction of T-ALL-derived mutant p53 expression constructs into T-ALL cell lines further increases their growth rate in culture, enhances cell cloning in methylcellulose, and increases tumor formation in nude mice.

Entities:  

Mesh:

Year:  1994        PMID: 8180387

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Inhibition of T-cell acute lymphoblastic leukemia proliferation in vivo by re-expression of the p16INK4a tumor suppressor gene.

Authors:  K Schoppmeyer; P S Norris; M Haas
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  WT1 mutations in T-ALL.

Authors:  Valeria Tosello; Marc R Mansour; Kelly Barnes; Maddalena Paganin; Maria Luisa Sulis; Sarah Jenkinson; Christopher G Allen; Rosemary E Gale; David C Linch; Teresa Palomero; Pedro Real; Vundavalli Murty; Xiaopan Yao; Susan M Richards; Anthony Goldstone; Jacob Rowe; Giuseppe Basso; Peter H Wiernik; Elisabeth Paietta; Rob Pieters; Martin Horstmann; Jules P P Meijerink; Adolfo A Ferrando
Journal:  Blood       Date:  2009-06-03       Impact factor: 22.113

3.  Apoptosis in haematological malignancies.

Authors:  J A DiGiuseppe; M B Kastan
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

4.  Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia.

Authors:  Renée M Demarest; Nadia Dahmane; Anthony J Capobianco
Journal:  Blood       Date:  2011-01-07       Impact factor: 22.113

5.  MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.

Authors:  L Gu; N Zhu; H W Findley; M Zhou
Journal:  Leukemia       Date:  2008-02-14       Impact factor: 11.528

6.  Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.

Authors:  M Hsiao; J Low; E Dorn; D Ku; P Pattengale; J Yeargin; M Haas
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

7.  Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.

Authors:  Koichi Oshima; Hossein Khiabanian; Ana C da Silva-Almeida; Gannie Tzoneva; Francesco Abate; Alberto Ambesi-Impiombato; Marta Sanchez-Martin; Zachary Carpenter; Alex Penson; Arianne Perez-Garcia; Cornelia Eckert; Concepción Nicolas; Milagros Balbin; Maria Luisa Sulis; Motohiro Kato; Katsuyoshi Koh; Maddalena Paganin; Giuseppe Basso; Julie M Gastier-Foster; Meenakshi Devidas; Mignon L Loh; Renate Kirschner-Schwabe; Teresa Palomero; Raul Rabadan; Adolfo A Ferrando
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-21       Impact factor: 11.205

8.  Loss of function tp53 mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish.

Authors:  Alejandro Gutierrez; Hui Feng; Kristen Stevenson; Donna S Neuberg; Oscar Calzada; Yi Zhou; David M Langenau; A Thomas Look
Journal:  Br J Haematol       Date:  2014-04-02       Impact factor: 6.998

9.  Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balance.

Authors:  Min Li; Xiang Zhang; Wen-jing Zhou; Yue-hua Chen; Hui Liu; Lin Liu; Chun-mei Yang; Wen-bin Qan
Journal:  Acta Pharmacol Sin       Date:  2013-11-18       Impact factor: 6.150

10.  The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status.

Authors:  Valentina Turinetto; Paola Porcedda; Luca Orlando; Mario De Marchi; Antonio Amoroso; Claudia Giachino
Journal:  BMC Cancer       Date:  2009-08-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.